What is Zacks Research’s Forecast for PBYI Q2 Earnings?

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Stock analysts at Zacks Research reduced their Q2 2025 earnings per share (EPS) estimates for Puma Biotechnology in a research report issued on Wednesday, April 30th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.08 per share for the quarter, down from their previous forecast of $0.09. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s FY2025 earnings at $0.48 EPS, Q3 2026 earnings at $0.13 EPS and Q4 2026 earnings at $0.02 EPS.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The business had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million.

A number of other brokerages have also weighed in on PBYI. StockNews.com upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, February 28th.

Puma Biotechnology Trading Up 4.2 %

PBYI opened at $3.21 on Friday. The company’s 50 day moving average is $3.13 and its 200-day moving average is $3.03. The company has a market cap of $159.32 million, a P/E ratio of 6.69 and a beta of 1.29. Puma Biotechnology has a 1-year low of $2.23 and a 1-year high of $5.26. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Institutional Investors Weigh In On Puma Biotechnology

Institutional investors have recently added to or reduced their stakes in the business. Bailard Inc. acquired a new position in shares of Puma Biotechnology during the first quarter worth $73,000. Bank of New York Mellon Corp raised its position in Puma Biotechnology by 2.7% during the 1st quarter. Bank of New York Mellon Corp now owns 340,886 shares of the biopharmaceutical company’s stock worth $1,009,000 after purchasing an additional 9,033 shares during the last quarter. PFG Investments LLC acquired a new position in Puma Biotechnology during the 1st quarter worth about $59,000. Mackenzie Financial Corp bought a new stake in shares of Puma Biotechnology in the 4th quarter valued at about $240,000. Finally, Two Sigma Investments LP raised its position in shares of Puma Biotechnology by 266.2% during the fourth quarter. Two Sigma Investments LP now owns 181,471 shares of the biopharmaceutical company’s stock worth $553,000 after acquiring an additional 131,916 shares during the last quarter. 61.29% of the stock is owned by institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.